PE Tech Report


Like this article?

Sign up to our free newsletter

Inflazome closes USD17m financing from Novartis Venture Fund and Fountain Healthcare Partners

Inflazome has closed a Series A financing round for up to USD17 million (EUR15 million), led by life sciences venture capital firms Novartis Venture Funds and Fountain Healthcare Partners.

Inflazome is developing inhibitors of the inflammasome, a biological target that regulates the innate immune response, now associated with a wide variety of diseases.
Following the closure of the financing round, Florent Gros, managing director of Novartis Venture Fund, and Dr Manus Rogan, co-founder and managing director at Fountain Healthcare Partners, have joined the board of directors.
Dr Matt Cooper, co-founder and CEO of Inflazome, says: “Inflammasome activation is now implicated in many diseases driven by chronic inflammation, from Parkinson’s to Asthma. These conditions are often inadequately treated by current therapies. We want to help people with debilitating diseases facing limited or no treatment options.”
Rogan says: “Considering the breadth and depth of possible applications, the commercial potential for a successful small molecule inhibitor of this key target is clearly in the billions of dollars range.”
Gros adds: “We have searched extensively for inhibitors of the inflammasome. We are very excited by Inflazome's prospects; the company has outstanding assets, expertise and capabilities.”

Like this article? Sign up to our free newsletter